Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846738 | 0.86 | ALDH1A1 (0.57) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL2390066 | 0.86 | ALDH1A1 (0.60) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL1849303 | 0.84 | TDP1 (0.61) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL27927948 | 0.83 | ALDH1A1 (0.67) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL2390050 | 0.83 | ALDH1A1 (0.54) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL2389164 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL6977707 | 0.80 | MAPT (0.62) | ALDH1A1MAPTLMNASMN1; SMN2MAPK1 | |
| SCHEMBL6815260 | 0.78 | GAA (0.69) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL2461666 | 0.77 | ALDH1A1 (0.66) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 | |
| SCHEMBL30464734 | 0.77 | ALDH1A1 (0.66) | ALDH1A1HPGDMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160283652-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | ALDH1A1 1948/4885HPGD 1491/4885MAPT 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.